HomeBUSINESS
BUSINESS

Astellas/Pfizer Amend Xtandi Trial Protocol, Topline Data Due Out This Year
(Jun.12.2017)

Astellas Pharma and Pfizer said on June 9 that they have revised the protocol of a global PIII study, dubbed PROSPER, evaluating Xtandi (enzalutamide) for non-metastatic castration-resistant prostate cancer (CRPC), with its topline data readout now expected for later this year ...
(LOG IN FOR FULL STORY)

News Calendar